Prempro
Company: Wyeth-Ayerst Laboratories
Approval Status: Approved January 1998
Treatment for: Hormone replacement therapy
Areas: Endocrinology; Obstetrics/Gynecology
Possible similar drugs: Prempro & Premphase
| General Information | Side Effects |
General Information
Prempro has been cleared for marketing with a new, increased progestin dose. The new dose of Prempro (conjugated estrogens/medroxyprogesterone acetate tablets) contains 0.625 mg Premarin (conjugated estrogens) and 5 mg medroxyprogesterone acetate. The previously approved dose contains 0.625 mg Premarin and 2.5 mg medroxyprogesterone acetate. The drug is approved for use as a combination estrogen and progestin hormone replacement therapy.
Side Effects
Common side effects may include nausea, breast tenderness, headaches, and abdominal pain.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
